Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 1998

View Archived Issues

Imutec reports positive phase I/II results for Virulizin

Maracenines: isolation and characterization of new antibacterial agents

MMP inhibitors in early development at British Biotech

Antiadhesion agents prepared and evaluated at Hoechst

First small-molecule G-CSF mimic synthesized by SB-Ligand team

PJ-1, an antiplatelet compound with a dual mechanism of action

Positive clinical trial results reported for HTF-919

Substituted pyrimidines from Amgen inhibit cytokine production

Bradykinin B2 antagonists in the pipeline at Fournier

Maruishi licenses rights to Chirocaine in Japan

Broad-spectrum parenteral cephalosporin launched this week in Japan

Zeneca acquires Australian pharmaceuticals business

EMD-122946, a potent and orally active ETA antagonist looks promising in preclinical studies

L-375052, a potent thrombin inhibitor with improved pharmacokinetics

Isoxazoline- and isoxazole-containing factor Xa inhibitors prepared by DuPont

Candidate oral fibrinogen receptor antagonist presented by Uriach at ACS meeting

Potent, orally active, second-generation neuroimmunophilin from Guilford

Invicorp trial results highlighted at recent congress

DMP-695: ACS debut for new, orally active CRF1 antagonist

MDX-CD4 development progresses, triggering milestone payment from Eisai

Lilly and Synaptic enter late-stage trials with antimigraine agent

Oral osteoporosis product developed by Lilly and Emisphere heads for clinical trials

Efficacy and safety of sublingual apomorphine in treatment of MED

Hyaluronic acid oligosaccharides inhibit tumor metastasis

Bayer, Fournier to copromote statin in some EU countries

FDA indicates approvability of DepoCyt for neoplastic meningitis from lymphomas

Enbrel efficacy demonstrated in juvenile RA patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...